絞り込み

16646

広告

Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.

著者 Agarwal MG , Gundavda MK , Gupta R , Reddy R
Clin Orthop Relat Res.2018 Sep ; 476(9):1773-1782.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (44view , 0users)

Full Text Sources

Medical

Although giant cell tumors (GCTs) are benign, their aggressiveness and tendency to recur locally challenge the orthopaedic surgeon's ability to perform joint-preserving intralesional surgery with an acceptably low risk of local recurrence. Denosumab has emerged as a possible medical treatment of GCT because it seems to halt the progression of GCT, alleviate pain, and increase perilesional bone formation, but its exact role has been questioned, and specifically its efficacy and associated complications are not well characterized.
PMID: 30794215 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード